Zobrazeno 1 - 5
of 5
pro vyhledávání: '"KHALED ELHADY MOHAMED"'
Autor:
Khaled Elhady Mohamed, Anna Thorsø Larsen, Simone Melander, Frederik Andersen, Ellen Barendorff Kerrn, Morten Asser Karsdal, Kim Henriksen
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Background Despite the extensive research to provide a disease-modifying osteoarthritis drug (DMOAD), there is still no approved DMOAD. Dual amylin and calcitonin receptor agonists (DACRA) can provide metabolic benefits along with antinocice
Externí odkaz:
https://doaj.org/article/3573830610a348da9a886335d22b38fc
Autor:
ANNA T. LARSEN, NINA SONNE, KHALED ELHADY MOHAMED, EMMA-MARIE BREDTOFT, FREDERIK ANDERSEN, MORTEN A. KARSDAL, KIM HENRIKSEN
Publikováno v:
Diabetes. 71
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for treatment of type 2 diabetes (T2D) and obesity due to their beneficial effects on both body weight, glucose control and insulin action. Cagrilintide, which is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25517a532ff0850702c45c3b16a56cfb
https://doi.org/10.2337/db22-823-p
https://doi.org/10.2337/db22-823-p
Autor:
Anne Aubert-Pouëssel, Joël Chopineau, Jean-Marie Devoisselle, Marie Morille, Pierre Martineau, Khaled Elhady Mohamed, Laurence Guglielmi, Philippe Legrand, Sarah Le Saux
Publikováno v:
Advanced Drug Delivery Reviews
Advanced Drug Delivery Reviews, Elsevier, 2021, pp.113837. ⟨10.1016/j.addr.2021.113837⟩
Advanced Drug Delivery Reviews, Elsevier, 2021, pp.113837. ⟨10.1016/j.addr.2021.113837⟩
Compared to chemicals that continue to dominate the overall pharmaceutical market, protein therapeutics offer the advantages of higher specificity, greater activity, and reduced toxicity. While nearly all existing therapeutic proteins were developed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5e8b81ff77c28b21ace0b941b0b8856
https://hal.archives-ouvertes.fr/hal-03292014
https://hal.archives-ouvertes.fr/hal-03292014
Autor:
Anne Aubert-Pouëssel, Khaled Elhady Mohamed, Joël Chopineau, Laurence Guglielmi, Lyria Ouchait, Jean-Marie Devoisselle, Pierre Martineau, Sarah Le Saux, Marie Morille, Philippe Legrand
Publikováno v:
Advanced Therapeutics
Advanced Therapeutics, 2021, pp.2100009. ⟨10.1002/adtp.202100009⟩
Advanced Therapeutics, Wiley, 2021, pp.2100009. ⟨10.1002/adtp.202100009⟩
Advanced Therapeutics, 2021, pp.2100009. ⟨10.1002/adtp.202100009⟩
Advanced Therapeutics, Wiley, 2021, pp.2100009. ⟨10.1002/adtp.202100009⟩
International audience; From recombinant insulin to monoclonal antibodies, proteins have become essential drugs in the therapeutic arsenal and respond to a broad spectrum of diseases. While commercially available proteins have an extracellular activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed07bef8a9dc455bb8563574cc17e50c
https://hal.science/hal-03210215
https://hal.science/hal-03210215
Autor:
Thierry Fournier, Louise Fliedel, Karine Andrieux, Khair Alhareth, Nathalie Mignet, Khaled Elhady Mohamed, Lucie Valero, Sophie Gil, Caroline Roques
Publikováno v:
International Journal of Pharmaceutics. 567:118479
Controlled distribution of a drug by its association to a nanocarrier is a promising approach for the treatment of pregnancy disorders such as preeclampsia. For this application, tracking both the nanocarrier and the drug is necessary to ensure the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1373de6db6508289693a2f0ab87e9cbc
https://doi.org/10.1016/j.ijpharm.2019.118479
https://doi.org/10.1016/j.ijpharm.2019.118479